搜索筛选:
搜索耗时0.0854秒,为你在为你在102,285,761篇论文里面共找到 9 篇相符的论文内容
发布年度:
[会议论文] 作者：Huiling Xiong,Zhiying Wu,
来源：第十二届全国神经病学学术会议 年份：2009
...
[会议论文] 作者：Yaming Yang,yuwen CHEN,huiling XIONG,shaoran LIU,
来源：第67届世界药学大会(67th International Conference of FIP) 年份：2007
...
[会议论文] 作者：Huiling Xiong,Xiaoyu Shi,Ying Zhou,Wenlin Li,
来源：第五届全国生物信息学与系统生物学学术大会 年份：2012
Background: IL-13 which is produced by a variety of cells, mainly by activated type Ⅱ T helper cells, is a multi-effectiveness of cytokines.It has confirmed that IL-13 is the primary cytokine that ind...
[会议论文] 作者：Shukui Qin,Ho yeong Lim,Baek-yeol Ryoo,Cindy Li,Huiling Xiong,Christian Ihling,Ann-lii Cheng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: The overall prognosis of advanced hepatocellular cancer (HCC) remains poor, with c-Met abnormalities associated with a particularly poor prognosis.The highly selective c-Met inhibitor tepot...
First-line tepotinib (MSC2156119J), an oral c-Met inhibitor, versus sorafenib in Asian patients with
[会议论文] 作者：Shukui Qin,Ho yeong Lim,Baek-yeol Ryoo,Cindy Li,Huiling Xiong,Andreas Johne,Ann-lii Cheng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Huiling Xiong,Cindy Li,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156...
Phase Ⅱ trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in Asian patients with gef
[会议论文] 作者：Yilong Wu,Keunchil Park,Dongwan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: The combination of the highly selective c-Met inhibitor tepotinib (MSC2156119J) + gefitinib was shown to be well tolerated and have antitumor activity possibly associated with c-Met-positi...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156119J) had promising activity in a phase Ⅰ tr...
[期刊论文] 作者：刘育松,张平祥,李成山,于泽铭,郑会玲,熊晓梅,刘奉生,王庆阳,姜冰,冯勇,周廉,Liu Yusong,Zhang Pingxing,Li Chengshan,Yu Zeming,Zheng Huiling,Xiong,
来源：稀有金属材料与工程 年份：2004
为了提高Bi-2212/Ag带的性能(主要指临界电流密度Jc),进行了部分熔化热处理工艺对带材Jc的实验.采用标准的4点法测量Jc,使用PW1700 XRD、SL20 SEM和EDX检验和研究带材的相组...
相关搜索：
